-
1.发明授权RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma 有权RNAi相关抑制TNFα信号通路治疗青光眼公开(公告)号：US08865670B2
公开(公告)日：2014-10-21
申请号：US13024621
申请日：2011-02-10
CPC分类号： C12N15/1138 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这种TNFα靶标可用于治疗患有TNFα相关病症的患者或具有发展TNFα相关病症的风险，例如与眼内压升高（IOP）相关的眼部病症，包括青光眼和高眼压症。
-
2.发明申请METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR 审中-公开使用抗炎剂和受体酪氨酸激酶抑制剂治疗乳腺癌和卵巢血管发生的方法公开(公告)号：US20090105245A1
公开(公告)日：2009-04-23
申请号：US11962338
申请日：2007-12-21
申请人： David P. Bingaman
发明人： David P. Bingaman
IPC分类号： A61K31/5377 , A61K31/423 , A61K31/416
CPC分类号： A61K45/06 , A61K31/416 , A61K31/423 , A61K31/5377 , A61K2300/00
摘要： The present invention provides methods for inhibiting increased vascular permeability and/or pathologic ocular angiogenesis via administration of a combination of one or more molecules that potently inhibit select receptor tyrosine kinases (RTKs) or vascular endothelial growth factor (VEGF) and one or more anti-inflammatory agents.
摘要翻译： 本发明提供了通过施用一种或多种有效抑制选择性受体酪氨酸激酶（RTK）或血管内皮生长因子（VEGF）的一种或多种分子的组合来抑制血管通透性和/或病理性眼血管发生增加的方法， 炎症剂。
-
3.发明申请RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA 审中-公开用于治疗乳腺癌的TNFα信号通路的RNAi相关性抑制公开(公告)号：US20090036397A1
公开(公告)日：2009-02-05
申请号：US12185182
申请日：2008-08-04
IPC分类号： A61K31/713 , A61P27/02
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFalpha）。 特别是沉默这种TNFα靶标对于治疗患有或有发生黄斑水肿危险的患者是有用的。
-
4.发明申请公开(公告)号：US20120245217A1
公开(公告)日：2012-09-27
申请号：US13474405
申请日：2012-05-17
IPC分类号： A61K31/7105 , A61P7/10 , A61P9/10 , A61K31/713 , A61P27/02
CPC分类号： C12N15/1136 , A61K9/0048 , A61K31/7105 , A61K31/713 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/30 , C12N2320/31
摘要： RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
摘要翻译： 提供RNA干扰用于抑制HIF1A mRNA表达，用于治疗眼血管发生的患者，特别是用于治疗视网膜水肿，糖尿病性视网膜病变，与视网膜缺血相关的后遗症，后段新生血管形成（PSNV）和新生血管性青光眼，并用于治疗患有风险的患者 发展这样的条件。
-
5.发明授权公开(公告)号：US07981870B2
公开(公告)日：2011-07-19
申请号：US12706014
申请日：2010-02-16
CPC分类号： C12N15/1136 , A61K9/0048 , A61K31/7105 , A61K31/713 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/30 , C12N2320/31
摘要： RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
摘要翻译： 提供RNA干扰用于抑制HIF1A mRNA表达，用于治疗眼血管发生的患者，特别是用于治疗视网膜水肿，糖尿病性视网膜病变，与视网膜缺血相关的后遗症，后段新生血管形成（PSNV）和新生血管性青光眼，并用于治疗患有风险的患者 发展这样的条件。
-
6.发明申请RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA 有权用于治疗GLAUCOMA的TNFα信号途径的RNAi相关性抑制公开(公告)号：US20110135579A1
公开(公告)日：2011-06-09
申请号：US13024621
申请日：2011-02-10
IPC分类号： A61K31/713 , A61K9/12 , A61P27/02
CPC分类号： C12N15/1138 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这种TNFα靶标可用于治疗患有TNFα相关病症的患者或具有发展TNFα相关病症的风险，例如与眼内压升高（IOP）相关的眼部病症，包括青光眼和高眼压症。
-
7.发明申请RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS 审中-公开肿瘤坏死因子信号通路治疗眼内血管生成的RNAi相关性抑制公开(公告)号：US20100267811A1
公开(公告)日：2010-10-21
申请号：US12825552
申请日：2010-06-29
IPC分类号： A61K31/713 , C07H21/02 , A61P27/02
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症如眼血管生成，视网膜缺血和糖尿病性视网膜病变的风险的患者。
-
8.发明申请AGENTS FOR TREATMENT OF DIABETIC RETINOPATHY AND DRUSEN FORMATION IN MACULAR DEGENERATION 审中-公开用于治疗糖尿病肾病和乳腺癌形成的代谢物公开(公告)号：US20100204244A1
公开(公告)日：2010-08-12
申请号：US12715853
申请日：2010-03-02
IPC分类号： A61K31/497 , A61K31/05 , A61K31/21 , A61K31/122 , A61K31/095 , A61K31/085 , A61K31/352 , A61K31/145 , A61K31/47 , A61P27/02 , A61P25/00
CPC分类号： A61K31/26 , A61K31/352 , A61K31/497
摘要： Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating diabetic retinopathy or drusen formation in age-related macular degeneration. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid other than genistein, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.
摘要翻译： 在年龄相关性黄斑变性中治疗糖尿病性视网膜病变或玻璃疣形成的方法中提供了刺激Nrf2蛋白的核易位和随后增加解毒和消除细胞毒性代谢物的基因产物的试剂。 作用于Nrf2 / ARE途径的结构不同的试剂诱导具有化学通用的细胞保护性质的酶和蛋白质的表达，并且是防止有毒代谢物和异生物。 药剂包括某些亲电试剂和氧化剂如迈克尔加成受体，二酚，硫代氨基甲酸酯，醌，1,2-二硫杂环戊烯-3-硫酮，丁基化羟基苯甲醚，除了染料木黄酮以外的类黄酮，异硫氰酸酯，3,5-二叔丁基 - 4-羟基甲苯，乙氧喹，香豆素，其组合，或其药理活性衍生物或类似物。
-
9.发明申请METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR 审中-公开使用神经保护剂和受体酪氨酸激酶抑制剂治疗恶性肿瘤和病理性血管生成的方法公开(公告)号：US20080153819A1
公开(公告)日：2008-06-26
申请号：US11963079
申请日：2007-12-21
IPC分类号： A61K31/5377 , A61K31/42 , A61K31/4184 , A61P27/02
CPC分类号： A61K31/42 , A61K31/416
摘要： The present invention provides methods for inhibiting increased vascular permeability and/or pathologic ocular angiogenesis and providing neuroprotection of the affected retina via administration of a combination of one or more molecules that potently inhibit select receptor tyrosine kinases (RTKs) or vascular endothelial growth factor (VEGF) and one or more neuroprotectants.
摘要翻译： 本发明提供了通过施用有效抑制选择性受体酪氨酸激酶（RTK）或血管内皮生长因子（VEGF）的一种或多种分子的组合来抑制增加的血管通透性和/或病理性眼血管生成并提供受影响的视网膜的神经保护的方法 ）和一种或多种神经保护剂。
-
10.发明授权RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis 有权RNAi相关抑制TNFα信号通路治疗眼血管生成公开(公告)号：US08754202B2
公开(公告)日：2014-06-17
申请号：US13169549
申请日：2011-06-27
IPC分类号： C07H21/04
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症如眼血管生成，视网膜缺血和糖尿病性视网膜病变的风险的患者。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.017 秒)